ArticleAsia Pacific journal of clinical nutrition2026
Inverse correlation between plasma 3-chlorotyrosine and pinch strength in chronic kidney disease patients.
Article in Asia Pacific journal of clinical nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
objectivesThis cross-sectional study aimed to explore whether plasma myeloperoxidase (MPO) and its active product, 3-chlorotyrosine (3-CT), as markers of inflammation and oxidative stress, have any independent pathophysiological association with sarcopenia-related parameters in patients with chronic kidney disease (CKD). METHODS AND STUDY
designA total of 292 patients, including 147 on maintenance hemodialysis (HD) and 145 non-dialyzed hospitalized patients with CKD stages 1-5, were enrolled from September 2022 to December 2023 and categorized into three groups: CKD stages 1-2, CKD stages 3-5 (non-dialysis), and CKD stage 5 (HD). Clinical data, anthropometric measurements, and body composition via bioelectrical impedance analysis were collected. Plasma MPO and 3-CT levels were measured by enzyme-linked immunosorbent assay and liquid chromatography-mass spectrometry (LC-MS), respectively.
resultsResults showed that as kidney function declined, plasma MPO levels significantly increased across the CKD stage 1-2, stage 3-5, and HD groups [93.5 (72.3, 103.0) ng/mL, 90.8 (76.0, 106) ng/mL, and 102 (80.7, 126) ng/mL, respectively; H = 174, p <0.001]. The prevalence of sarcopenia also increased significantly across CKD stages (17.3%, 17.1%, and 29.9%, respectively; χ² = 6.52, p = 0.038). Interestingly, statistical analysis confirmed a significant inverse association between plasma 3-CT levels and pinch strength (r = -0.148, p = 0.036). However, there were no significant correlation between plasma MPO or 3-CT levels and sarcopenia.
conclusionsThe negative association between plasma 3-CT and pinch strength suggests a link between MPO-mediated inflammation/oxidative stress and fine hand muscle dysfunction, which provides a new perspective for evaluating early, subclinical muscle dysfunction in CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.